Story perspectives

White House Rejects Rumor Trump Received Early Lilly Obesity Drug

6/26/2026

Summary

Story summary

The White House publicly refuted rumors that President Donald Trump received early access to Eli Lilly’s experimental obesity drug retatrutide.
An FDA compassionate-use program administered retatrutide to a 79-year-old patient after NIH senior clinician Ranganath Muniyappa submitted an April request for a patient with refractory obesity, obstructive sleep apnea and pulmonary hypertension.
President Donald Trump’s May 2026 physical listed his weight at 238 lb and his physician said he remains in excellent health.

History

Historical Context

Since the 1978 Randall decision created a compassionate-use program, the FDA began allowing experimental drugs such as Novartis’s imatinib to reach patients, a practice reinforced by the AIDS-era accelerated-approval rules of the late 1980s and the 2006 Abigail Alliance case; these precedents frame today’s scrutiny of Trump’s denied early access to Eli Lilly’s retatrutide.

1 of 2

Story summary

The White House publicly refuted rumors that President Donald Trump received early access to Eli Lilly’s experimental obesity drug retatrutide.
An FDA compassionate-use program administered retatrutide to a 79-year-old patient after NIH senior clinician Ranganath Muniyappa submitted an April request for a patient with refractory obesity, obstructive sleep apnea and pulmonary hypertension.
President Donald Trump’s May 2026 physical listed his weight at 238 lb and his physician said he remains in excellent health.

1 / 2